4170
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei C… Read more
Market Cap & Net Worth: 4170 (4170)
4170 (TWO:4170) has a market capitalization of $17.86 Million (NT$590.91 Million) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #27267 globally and #1725 in its home market, demonstrating a -4.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 4170's stock price NT$13.50 by its total outstanding shares 43771370 (43.77 Million).
4170 Market Cap History: 2026 to 2026
4170's market capitalization history from 2026 to 2026. Data shows growth from $17.86 Million to $17.86 Million (0.00% CAGR).
4170 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 4170's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4170 by Market Capitalization
Companies near 4170 in the global market cap rankings as of March 19, 2026.
Key companies related to 4170 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
4170 Historical Marketcap From 2026 to 2026
Between 2026 and today, 4170's market cap moved from $17.86 Million to $ 17.86 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$17.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of 4170 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.86 Million USD |
| MoneyControl | $17.86 Million USD |
| MarketWatch | $17.86 Million USD |
| marketcap.company | $17.86 Million USD |
| Reuters | $17.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.